Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Concordia framed AMCo as a transatlantic specialty platform; commentators flagged the Valeant comparison and high leverage ratio as risk factors.
Deal characterized as creating a 'global platform' with 190+ molecules and 100+ country reach, financed with $2.8B debt + $520M equity raise.
UK CMA issued Statement of Objections to Concordia on liothyronine pricing — one of the legacy AMCo molecules — confirming post-deal regulatory liability.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Concordia Healthcare acquired Amdipharm Mercury Limited (AMCo) from Cinven for approximately $3.5B (~$1.2B cash + 8.49M shares + $1.4B assumed debt + up to $220M earn-out), gaining 190+ off-patent specialty products with reach in 100+ countries. Closed October 21, 2015. Concordia later collapsed under debt and rebranded as Advanz Pharma.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Concordia Healthcare Corp. / Amdipharm Mercury Limited (AMCo) (this deal) | 2015 | $3.5B | 16 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Cephalon Inc. / Mepha AG | 2010 | $615M | 23 |
| Takeda Pharmaceutical Company Ltd. / Nabla Bio, Inc. | 2025 | $1.0B | — |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
← Browse all deals · How we score deals
More: 2015 deals · Multiple deals